+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-alpha (cachectin)



Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-alpha (cachectin)



Endocrinology 125(1): 76-84



Tumor necrosis factor-alpha (TNF; cachectin), a peptide secreted from stimulated macrophages, mediates some of the metabolic derangements in inflammatory and neoplastic disorders. To determine whether TNF is responsible for the changes in hypothalamic-pituitary-thyroid (HPT) function in nonthyroid illnesses, we administered synthetic human TNF to male Sprague-Dawley rats. The rats were given TNF or saline (control; both pair fed and nonpair fed) iv (six to eight per group). HPT function was tested 8 h after administration of 200 micrograms TNF/kg BW, 8 h after 5 days of 150 micrograms TNF/kg BW, and 8 h after a 3-day series of 50, 200, and 800 micrograms TNF/kg BW. The single injection of 200 micrograms TNF/kg significantly reduced (all P less than 0.05) serum TSH, T4, free T4, T3, and hypothalamic TRH compared to the corresponding hormone levels in saline-injected control rats. Serum TSH and hypothalamic TRH recovered to normal levels after 5 days of 150 micrograms/kg TNF treatment. With the increasing daily doses of TNF, serum TSH and hypothalamic TRH fell significantly. Hepatic 5'-deiodinase activity was reduced after 1 day of TNF treatment, but increased after the 3-day series of injections. TNF treatment reduced pituitary TSH beta mRNA, but did not affect alpha-subunit mRNA. TNF treatment also reduced thyroid 125I uptake and reduced thyroidal release of T4 and T3 in response to bovine TSH, but did not change the TSH response to TRH. TNF treatment reduced the binding of pituitary TSH to Concanavalin-A, indicating that it alters the glycosylation of TSH. The TSH with reduced affinity for this lectin had reduced biological activity when tested in cultured FRTL-5 rat thyroid cells. In vitro, TNF inhibited 125I uptake by cultured FRTL-5 rat thyroid cells and blocked the stimulation of [3H]thymidine uptake by these cells. The data indicate that TNF acts on the HPT axis at multiple levels and suggest that TNF is one of the mediators responsible for alterations in thyroid function tests in patients with nonthyroidal illnesses.

(PDF emailed within 0-6 h: $19.90)

Accession: 040374495

Download citation: RISBibTeXText

PMID: 2500334

DOI: 10.1210/endo-125-1-76


Related references

Increased spontaneous release of tumor necrosis factor-alpha/cachectin in headache patients. A possible correlation with plasma endotoxin and hypothalamic-pituitary-adrenal axis. International Journal of Neuroscience 61(1-2): 53-60, 1991

Survival of cfu c from x irradiated murine long term bone marrow cultures ltbmc treated with recombinant human tumor necrosis factor cachectin tnf. Experimental Hematology 19(6): 520, 1991

Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells. Journal of Immunology 138(12): 4298-4302, 1987

Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes. Molecular and Cellular Biology 8(6): 2394-2401, 1988

Induction of dermal and subcutaneous inflammation by recombinant cachectin/tumor necrosis factor (TNF alpha) in the mouse. Journal of Investigative Dermatology 91(4): 353-357, 1988

Effect of age on hypothalamic prostaglandin e 2 production and fever in response to tumor necrosis factor cachectin and endotoxin in rats. Clinical Science 81(3): 313-318, 1991

Effects of tumor necrosis factor-alpha/cachectin on thyroid hormone metabolism in mice. Endocrinology 123(3): 1461-1467, 1988

Human recombinant interleukin 1 beta and alpha but not recombinant tumor necrosis factor alpha stimulate acth release from rat anterior pituitary cells in vitro in a prostaglandin e 2 and cyclic amp independent manner. Neuroendocrinology 48(2): 160-166, 1988

Crystallization of trimeric recombinant human tumor necrosis factor (cachectin). Journal of Biological Chemistry 263(26): 12816-9, 1988

Recombinant human tumor necrosis factor cachectin is an endogenous pyrogen and induces interleukin 1. Clinical Research 34(2): 675A, 1986

Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin. Biochemical and Biophysical Research Communications 137(2): 847-854, 1986

Identification of a novel tumor necrosis factor alpha/cachectin from the livers of burned and infected rats. Archives of Surgery 125(1): 79-84; Discussion 85, 1990

Effects of recombinant human interleukin 2 il 2 and tumor necrosis factor alpha tnf alpha with or without interferon gamma ifn alpha on human thyroid tissues from patients with graves disease and normal subjects xenografted into nude mice. Clinical Research 39(2): 376A, 1991

Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. Journal of Clinical Investigation 86(6): 2014-2024, 1990

Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. Journal of Experimental Medicine 169(6): 2021-2027, 1989